Researchers at the 2024 American Society of Hematology Annual Meeting said follicular lymphoma is biologically diverse. The evolving role of HSCT aAHSCT, and allo-HSCT requires further clarification amid new treatment advances in WM. Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL. Treatment choice significantly influences outcomes in patients with mantle cell lymphoma. The efficacy of HSCT for FL and provides a benchmark for testing emerging therapies like CAR-T and bispecific antibodies. Researchers generated Patient-Derived Lymphoma Tumoroids to replicate the FL tumor microenvironment. Researchers at ASH 2024 explained that adolescents and young adults with non-Hodgkin lymphoma face fertility challenges. Future studies should explore combining allo-HSCT with novel therapies to enhance outcomes further. The functional and structural relevance of IGHV1-204 remains unclear for patients with splenic marginal zone lymphoma. A retrospective analysis observed 3,897 patients with lymphoma enrolled in 32 cooperative group trials between 2005 and 2020. Marginal zone lymphoma lacks extensive research on its real-world treatment patterns and economic impact. Patients with follicular lymphoma and early progression are a distinctly vulnerable population who need further study. A study stresses psychological support as an essential component of comprehensive cancer care. Good local control over five years using a very low dose approach was possible for potentially curable patients. A phase I/II first-in-human study evaluates a new bivalent small molecule in relapsed or refractory FL and MZL. Study investigated if high Vulnerable Elders Survey scores were associated with changes in quality of life across age groups. A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M. The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population. CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain. The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.